Skip to main content
PONLIMSI (denosumab-adet) Injection 60 mg/mL

This site is for U.S. residents only

PONLIMSI™ (denosumab-adet)
Risk Evaluation and Mitigation Strategy

What is the PONLIMSI REMS?

A REMS (Risk Evaluation and Mitigation Strategy) is a program required by the Food and Drug Administration to manage known or potential serious risks associated with a drug product.

The purpose of the PONLIMSI REMS is to inform healthcare providers and patients about the following serious risk of:

  • Severe Hypocalcemia in Patients with Advanced Chronic Kidney Disease

The PONLIMSI REMS program materials are designed to inform healthcare providers and patients about this risk with PONLIMSI. The PONLIMSI REMS program materials include a REMS Letter for Healthcare Providers and a Patient Guide. It is important that you discuss with each patient the information included in the Patient Guide.

To learn more about the serious risk of PONLIMSI, read the Important Safety Information (PDF, opens in a new tab) provided in this link and use the links on the right to access REMS supporting materials.

Reporting Adverse Events

To report adverse reactions associated with PONLIMSI, please call Teva Pharmaceuticals, Inc. at 1-888-483-8279, option #2, or report the event at www.fda.gov/medwatch.